/
RFL
$3.16+$0.40 (+14.49%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$143.5M
52M shares
52-week range
$1.12 – $3.17
100% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Price (6 mo)
Loading chart…
Change$-47.89
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $4.9M | $4.9M | $802.0K | $410.0K | $279.0K | $637.0K | $917.0K |
| Cost of revenue | $0 | $0 | $0 | $70.0K | $0 | $0 | $154.0K | $422.0K |
| Gross profit | $4.4M | $4.9M | $4.9M | $802.0K | $410.0K | $279.0K | $483.0K | $495.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 75.8% | 54.0% |
| R&D | $995.0K | $1.0M | $2.4M | $4.9M | $8.7M | $6.3M | $94.0M | $12.8M |
| Operating income | −$3.8M | −$6.7M | −$8.5M | −$21.2M | −$60.5M | −$15.0M | −$102.6M | −$26.1M |
| EBITDA | −$1.9M | −$3.2M | −$5.0M | −$23.3M | −$139.9M | −$8.7M | −$66.8M | −$32.3M |
| Net income | −$11.6M | −$4.9M | −$10.4M | −$24.5M | −$124.7M | −$1.9M | −$34.4M | −$30.5M |
| Net margin | -266.5% | -99.9% | -212.1% | -3060.3% | -30404.4% | -672.4% | -5401.9% | -3328.2% |
| EPS (diluted) | -0.93 | -0.37 | -0.44 | -1.47 | -6.31 | -0.08 | -1.45 | -1.04 |
Annual figures · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.99
Price
$3.16
Implied downside
-69%
Peer comparison
Rafael Holdings, Inc. Class B Common Stock
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
www.rafaelholdings.com- Employees
- 23
- IPO / List date
- Mar 6, 2018
- HQ
- NEWARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds RFL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 89,138 | $111.4K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RFL yet.
